$620 Million is the total value of Darwin Global Management, Ltd.'s 12 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 83.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTLA | New | INTELLIA THERAPEUTICS INC | $301,141,000 | – | 1,859,926 | +100.0% | 48.58% | – |
| XLRN | Buy | ACCELERON PHARMA INC | $220,906,000 | +8.2% | 1,760,346 | +17.0% | 35.63% | -10.8% |
| FATE | Sell | FATE THERAPEUTICS INC | $29,154,000 | -74.2% | 335,918 | -75.5% | 4.70% | -78.7% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $20,532,000 | -84.1% | 336,817 | -83.9% | 3.31% | -86.9% |
| BEAM | New | BEAM THERAPEUTICS INC | $16,344,000 | – | 126,985 | +100.0% | 2.64% | – |
| VERV | New | VERVE THERAPEUTICS INC | $6,207,000 | – | 103,013 | +100.0% | 1.00% | – |
| INBX | Buy | INHIBRX INC | $6,205,000 | +521.7% | 225,480 | +353.6% | 1.00% | +413.3% |
| EPIX | New | ESSA PHARMA INC | $5,958,000 | – | 208,524 | +100.0% | 0.96% | – |
| KROS | Buy | KEROS THERAPEUTICS INC | $4,425,000 | -17.3% | 104,186 | +19.9% | 0.71% | -31.8% |
| ACRS | New | ACLARIS THERAPEUTICS INC | $4,390,000 | – | 250,000 | +100.0% | 0.71% | – |
| RLAY | Sell | RELAY THERAPEUTICS INC | $4,383,000 | -83.8% | 119,775 | -84.7% | 0.71% | -86.7% |
| GBIO | Sell | GENERATION BIO CO | $289,000 | -95.4% | 10,738 | -95.1% | 0.05% | -96.2% |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -49,868 | -100.0% | -0.12% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -65,849 | -100.0% | -0.21% | – |
| CCCC | Exit | C4 THERAPEUTICS INC | $0 | – | -140,034 | -100.0% | -1.01% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -286,195 | -100.0% | -1.78% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -140,511 | -100.0% | -1.82% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FATE THERAPEUTICS INC | 5 | Q4 2021 | 24.2% |
| KEROS THERAPEUTICS INC | 5 | Q1 2023 | 12.8% |
| INHIBRX INC | 5 | Q4 2021 | 3.9% |
| ACCELERON PHARMA INC | 4 | Q3 2021 | 63.4% |
| AMBRX BIOPHARMA INC | 4 | Q3 2023 | 67.5% |
| ARGENX SE | 4 | Q3 2023 | 70.2% |
| BRIDGEBIO PHARMA INC | 4 | Q3 2021 | 25.2% |
| FULCRUM THERAPEUTICS INC | 4 | Q4 2021 | 0.9% |
| ASTRAZENECA PLC | 3 | Q2 2022 | 100.0% |
| INTELLIA THERAPEUTICS INC | 3 | Q4 2021 | 48.6% |
View Darwin Global Management, Ltd.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-28 |
| SC 13D/A | 2023-06-28 |
| SC 13D/A | 2023-05-25 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-03 |
| 3 | 2023-03-08 |
View Darwin Global Management, Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.